Search Medical Condition
Please enter condition
Please choose location

Fujisawa-shi, Kanagawa, Japan Clinical Trials

A listing of Fujisawa-shi, Kanagawa, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (75) clinical trials

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

The maximum study duration per patient will be approximately 41 weeks: an up to 14-week screening period (consisting of an up to 2-week screening phase and a 12-week run-in phase), a 26-week randomized treatment period, and a 3-day post-treatment safety follow-up period.

Phase

0.0 miles

Learn More »

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

The maximum study duration per patient will be approximately 29 weeks: an up to 2-week screening period, a 26-week randomized open-label treatment period and a 3-day post-treatment safety follow up period.

Phase

0.0 miles

Learn More »

CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and ...

Phase

0.92 miles

Learn More »

Phase III Study of GSK1278863 in Japanese Non-dialysis and Peritoneal Dialysis Subjects With Renal Anemia

This is a Phase III, open-label, active-controlled, parallel-group, multi-center study to compare the efficacy (verification of noninferiority) and safety of GSK1278863 administered for 52 weeks versus epoetin beta pegol in approximately 270 Japanese non-dialysis (ND) and 50 peritoneal dialysis (PD) subjects with renal anemia. The study will consist of 2 ...

Phase

0.92 miles

Learn More »

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

This is an international, multicentre, parallel group, event-driven, randomized, double-blind, placebo-controlled study in patients with chronic heart failure with reduced ejection fraction (HFrEF), evaluating the effect of dapagliflozin versus placebo, given once daily in addition to background regional standard of care therapy, for the prevention of cardiovascular (CV) death or ...

Phase

0.92 miles

Learn More »

Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan

The objectives of study are to 1) determine the incidence of adverse events and adverse drug reactions among patients receiving evolocumab for up to 2 years, and 2) identify and describe patient characteristics (e.g. demographics, medical history) associated with the safety and effectiveness of evolocumab therapy for the patients with ...

Phase N/A

1.03 miles

Learn More »

EVOLVE Short DAPT Study

The primary objective of the EVOLVE Short DAPT Study is to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with the SYNERGY Stent System. The study will be conducted up to 120 sites worldwide in the United ...

Phase

2.25 miles

Learn More »

Long-Term Retention of Gadolinium in Bone

The purpose of the study is to further investigate the safety of six different commercially used Gadolinium-containing contrast agents. In order to get a better view of internal organs such as the brain, joints and other body regions contrast agents containing Gadolinium are often administered during magnetic resonance imaging. Gadolinium-containing ...

Phase

2.37 miles

Learn More »

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.

Phase

2.52 miles

Learn More »